Certain theoretical and practical considerations involved in evaluating the overall abuse potential of opiate agonists and antagonists.
D000818:Animals; D002746:Chlorpromazine / Q000494:pharmacology; D003061:Codeine / Q000494:pharmacology; D003496:Cyclazocine / Q000494:pharmacology; D004338:Drug Combinations; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D006801:Humans; D008238:Lysergic Acid Diethylamide / Q000494:pharmacology; D051379:Mice; D009019:Morphinans / Q000008:administration & dosage*; D009020:Morphine / Q000037:antagonists & inhibitors / Q000494:pharmacology; D009021:Morphine Dependence / Q000188:drug therapy; D009269:Nalorphine / Q000494:pharmacology; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D010424:Pentobarbital / Q000494:pharmacology; D051381:Rats; D011955:Receptors, Drug; D013045:Species Specificity; D013375:Substance Withdrawal Syndrome; D019966:Substance-Related Disorders / Q000188:drug therapy; D011795:Surveys and Questionnaires
D004338:Drug Combinations; D009019:Morphinans; D009292:Narcotic Antagonists; D011955:Receptors, Drug; D009270:Naloxone; D009020:Morphine; D008238:Lysergic Acid Diethylamide; D010424:Pentobarbital; D003496:Cyclazocine; D002746:Chlorpromazine; D009269:Nalorphine; D003061:Codeine